Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections

Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections

Immune checkpoint inhibitors (ICIs) have been widely used in the management of malignant tumors. Programmed death 1 (PD‐1)/PD‐1 ligand (PD‐L1) inhibitors have been introduced to treat non‐small cell lung cancer (NSCLC) in recent years. Currently, PD‐1/PD‐L1 inhibitors are considered to have minor si...

Full description

Bibliographic Details
Main Authors: Minya Lu, Li Zhang, Yue Li, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiaoyan Si, Yingchun Xu
Format: Article
Language:English
Published: Wiley 2020-03-01
Series:Thoracic Cancer
Subjects:
Immune checkpoint
immune‐related adverse events
infections
PD‐1/PD‐L1 inhibitors
Online Access:https://doi.org/10.1111/1759-7714.13313

Internet

https://doi.org/10.1111/1759-7714.13313

Similar Items